IP Library Patent Application 13439392
Patent Application
App. No. 13/439,392

HIGHLY PURIFIED ETHYL EPA AND OTHER EPA DERIVATIVES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/439,392
Abstract

A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided.

Claims (11)

1 . A pharmaceutical composition comprising eicosapentaenoic acid, wherein the composition contains no docosahexaenoic acid and the composition is present in a capsule.

2 . The composition of claim 1 wherein the composition contains less than 5% of any fatty acid other than eicosapentaenoic acid.

3 . The composition of claim 1 wherein the composition contains less than 3% of any fatty acid other than eicosapentaenoic acid.

4 . The composition of claim 2 wherein the eicosapentaenoic acid comprises ethyl-eicosapentaenoic acid, lithium-eicosapentaenoic acid, mono-, di- or triglyceride eicosapentaenoic acid, or an ester, salt or free acid of eicosapentaenoic acid.

5 . The composition of claim 4 wherein the eicosapentaenoic acid comprises ethyl-eicosapentaenoic acid or an ester thereof.

6 . The composition of claim 5 wherein the capsule is a gelatin capsule.

7 . The composition of claim 5 where the composition comprises at least 90% wt/wt ethyl-eicosapentaenoic acid or an ester thereof.

8 . The composition of claim 5 where the composition comprises at least 95% wt/wt ethyl-eicosapentaenoic acid or an ester thereof.

9 . The composition of any one of claims 1 - 8 wherein the eicosapentaenoic acid is present in the composition in an amount of 250 mg to 1000 mg.

10 . A pharmaceutical composition comprising 250 mg to 1000 mg of eicosapentaenoic acid, wherein the composition contains no docosahexaenoic acid, less than 5% of any fatty acid other than eicosapentaenoic acid, and the composition is present in a capsule.

11 . A pharmaceutical composition comprising 250 mg to 1000 mg of ethyl-eicosapentaenoic acid or an ester thereof, wherein the composition contains no docosahexaenoic acid, less than 5% of any fatty acid other than ethyl-eicosapentaenoic acid or an ester thereof, and the composition is present in a capsule.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Nov 19, 2020
From: CPPIB CREDIT EUROPE S.À R.L.
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 054484/0552 →
SECURITY INTEREST Recorded Dec 21, 2017
From: AMARIN PHARMACEUTICALS IRELAND LIMITED
To: CPPIB CREDIT EUROPE S.À R.L.
Reel/Frame 044938/0257 →
PATENT SECURITY ASSIGNMENT AND ASSUMPTION AGREEMENT Recorded Dec 20, 2017
From: BIOPHARMA SECURED DEBT FUND II HOLDINGS CAYMAN LP
To: CPPIB CREDIT EUROPE S.À R.L.
Reel/Frame 044956/0395 →
SECURITY AGREEMENT Recorded Dec 19, 2012
From: AMARIN PHARMACEUTICALS IRELAND LIMITED
To: BIOPHARMA SECURED DEBT FUND II HOLDINGS CAYMAN LP
Reel/Frame 029499/0087 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2012
From: AMARIN CORPORATION PLC
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 028351/0358 →
PROOF OF OWNERSHIP OF SHARES Recorded May 30, 2012
From: AMARIN NEUROSCIENCE LIMITED
To: AMARIN CORPORATION PLC
Reel/Frame 028301/0228 →
CHANGE OF NAME Recorded May 30, 2012
From: LAXDALE LIMITED
To: AMARIN NEUROSCIENCE LIMITED
Reel/Frame 028301/0246 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2012
From: PEET, MALCOLM; VADDADI, KRISHNA S.
To: LAXDALE LIMITED
Reel/Frame 028291/0162 →